As AI and automation reshape drug discovery, laboratories themselves are being forced to evolve. Gensler’s Ryley Poblete joins the podcast to explain how new technologies, the makeup of scientific teams and new ways of collaboration are changing lab design.
The FDA has approved the first true generic version of GSK's asthma inhaler Flovent, signing off on Glenmark's fluticasone propionate inhalation aerosol. For more than two years, Prasco Laboratories has sold an "authorized generic" version of the treatment.
After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S. generics to its multiple sclerosis blockbuster Mavenclad.
At a time when his vaccine policies are causing pushback from doctors, Kennedy's allies push nutrition education as an area of common ground.
Eli Lilly is going beyond its efforts to sell its obesity drug Zepbound directly to patients, and is now trying to target employers.
Galderma has doubled its peak annual sales estimate for Nemluvio (nemolizumab) to more than $4 billion, following what CEO Flemming Ørnskov described as an “outstanding launch trajectory” for the Dupixent competitor in its first full year on the market.
Leo Pharma has decided “It’s GO time” for the launch of its JAK inhibitor cream Anzupgo. Having built its growth plans on the recently approved medicine, the Danish drugmaker is running a direct-to-consumer campaign, including an ad on streaming services.
Cognito raised $105 million as it awaits trial data that it hopes will convince the FDA to authorize its Alzheimer’s treatment device.
Forma Life Sciences, which inherited BioDuro’s California operations earlier this year, officially launched as a CDMO with a focus on oral solid dosage drugs this week.
Scientists have uncovered a crucial weakness in the malaria parasite that could open the door to new treatments. Researchers identified a protein called Aurora-related kinase 1 (ARK1) that acts like a traffic controller during the parasite’s unusual cell division process, ensuring its genetic material is properly separated as it multiplies. When scientists switched off ARK1 in laboratory experimen
A new study found GLP-1 drugs were associated with 50% fewer substance-related deaths, 39% fewer drug overdoses, and 26% fewer drug-related hospitalizations.
A Justice Department lawyer argued that the HHS secretary has broad discretion to issue vaccine guidance and choose what evidence to consider.
A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy. In clinical trials, the treatment zorevunersen cut seizures by as much as 91% while also improving quality of life for many patients. The therapy works by boosting the function of a key gene involved in nerve cell signaling. Encouraging results have led researchers to launch
Popular weight-loss drugs such as Ozempic, Wegovy, and Mounjaro may do more than help people shed pounds. New research suggests these GLP-1 medications could also help protect the heart after a heart attack by restoring blood flow in tiny blood vessels that often remain blocked even after doctors reopen a major artery.
Daily aspirin does not reliably prevent bowel cancer in people at average risk, according to a major new review. Any potential protective effect may take more than a decade to appear — if it appears at all — and the evidence for that benefit is weak. In contrast, the risk of serious bleeding begins right away, even with low-dose aspirin. Experts warn that prevention decisions should be individuali
Eli Lilly has officially launched Employer Connect, its direct-to-employer platform for its obesity medications, after teasing the rollout late last year.
The warning comes as Kennedy is leaning heavily into his agenda to improve American diets
Stiff knees and aching hips may seem like an inevitable part of aging, but experts say we’re getting osteoarthritis all wrong. Despite affecting nearly 600 million people worldwide — and potentially a billion by 2050 — the most powerful treatment isn’t surgery or medication. It’s exercise. Movement nourishes cartilage, strengthens muscles, reduces inflammation, and even reshapes the biological pro
Collegium Pharmaceutical has tapped an appropriately glitzy star as the face of a new campaign spotlighting the bright side of life with attention-deficit/hyperactivity disorder.
BioDuro, headquartered in California, has set up a new joint venture with Taiwan drug ingredients manufacturer, Cenra API Solutions. The new enterprise will see Cenra’s commercial-scale facility in Taipei folded into BioDuro’s production network.